Delegates from the Acorn Regulatory clinical team are attending the 11th annual DIA QPPV forum in London. One of the main talking points at the conference has been the issue of Brexit and the impact that it will have on the role of the QPPV.
The bids are in and now the politicking begins. The EMA decision timeline is coming to an end. However, the most dramatic and interesting elements of the bid process are about to begin. We have a brief overview of what to expect between now and decision day.
Amsterdam is surely one of the leading cities competing to host the European Medicines Agency. According to Dutch news sources, the bid team are working hard to ensure that the city can host EMA staff and families by working to increase the availability of suitable housing and international school places.
In this blog Brian Cleary looks ahead to the highly anticipated speech in Florence by British PM Theresa May
One year on from the UK’s decision to leave the European Union the negotiations have begun. The life sciences sector is, perhaps, one of the sectors that will be most impacted by the result of the referendum and many companies are setting plans in place to deal with a new regulatory landscape. What are the […]